Logo

Solexa Closes $17M in Second Financing Round

Sep 24, 2001

NEW YORK, Sept. 24 – Solexa, a UK-based developer of high-throughput technology, has closed on roughly $12 million in its second round of venture capital financing, the company said on Monday.

Nick McCooke, Solexa's president and managing director, told GenomeWeb that the cash will be used to help create “the next generation of DNA sequencing tools.” McCooke reckons this recent cash infusion should be enough help the company meet that goal, which he said would likely happen within two years.

Schroder Ventre Life Sciences led the round, which was in negotiations since May, McCooke said.

Breaking News
The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.